Table 2.
Summary of commercial LMWH and ULMWH patent position including the principal claim defining the scope of patent (whether product, process, product-by-process patent) and the date of expiry
| LMWH | Patent | Current Owner/ Assignee | Filed on | Claim Type/Claim 1 | Patent Expiry |
|---|---|---|---|---|---|
| Dalteparin | EP0014184 | Pfizer Health/ Kabi AB |
07-01-1980 (08-01-1979 SE) |
“Compound/ Heparin fragments, characterized by 14-18 sugar units, the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-D-glucosamine-6-O-sulphate” | 18-10-2006 |
| US4303651 | Pfizer Health / Kabi AB |
04-01-1980 (08-01-1979 SE) |
“Compound/Heparin fragments having 14-18 sugar units, wherein the main component is the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-D-glucosamine-6-O-sulphate” | 04-01-2005 | |
| EP0048231 | Phadia AB/ Kabi AB |
10-09-1981 (15-09-1980 SE) |
“Compound/ Oligosaccharide comprising 4-8 monosaccharide units” | 29-06-2005 | |
| Enoxaparin | US4990502 | Sanofi-Aventis |
15-04-1988 (16-04-1987 FR) |
“Product / A composition of heparins of low molecular weight and their pharmaceutically acceptable salts” | 15-04-2008 |
| US4841041 |
Sanofi/ Akzo Nobel |
12-07-1988 (20-07-1987 EP) |
Product/ Pentasaccharide of the formula: | 12-07-2008 | |
| EP0287477 | Sanofi-Aventis |
15-04-1988 (16-04-1987 FR) |
“Product / Composition of heparins of which 90% have a molecular weight between 3,600 and 11,000 Da” | 15-04-2008 | |
| US5707973 | Aventis/Rhone Poulenc |
09-12-1994 (23-04-1991 FR) |
“Product/mixture of sulfated oligosaccharides having the structure of constituent oligosaccharides of heparin, that has a mean molecular mass of 6±0.6 kD” | 13-01-2015 | |
| US5389618 (Re-issued 38743) | Aventis/ Rhone Poulenc |
16-07-1993 (26-06-1990 FR) |
“Compound/heterogeneous intimate admixture of sulfated heparinic polysaccharides” | 14-02-2012 | |
| US5849721 | Aventis Pharma SA |
06-06-1995 (07-02-1992 FR) |
“Product / A mixture of sulphated oligosaccharides obtained from native or depolymerized heparin comprising at least 70% of oligosaccharides having a molecular weight between 5,400 and 7,800 daltons” | 15-12-2015 | |
| US6534481 | Sanfo-Sythelabo/Akzo Nobel |
08-07-1997 (19-07-1996 FR) |
“Product/Polysaccharide comprising a region for binding to antithrombin III consisting of a sequence of five monosaccharides bearing in total two carboxylic acid functions” | 08-07-2017 | |
| US6617316 | Aventis Pharma SA |
20-10-2000 (22-10-1999 FR) |
64118920891500“Compound/A purified oligosaccharide of formula”: | 14-02-2022 | |
| US6969705 | Aventis Pharma SA |
23-07-2001 (21-07-2000 FR) |
“Product/ A composition comprising at least one salt chosen from alkali and alkaline-earth metal salts of at least one sulphated polysaccharide of heparin” | 24-10-2021 | |
| US6608042 | Aventis Pharma SA |
26-03-2001 (28-03-2000 FR) |
70231030099000“Product/pharmaceutical composition comprising one or more oligosaccharides of formula”: | 26-03-2021 | |
| US7956046 | Aventis Pharma SA |
27-07-2004 (24-07-2003 FR) |
“Compound/An oligosaccharide mixture, wherein: the oligosaccharide mixture comprises an anti-Xa activity of from 200 IU/mg to 450 IU/mg” | 22-03-2026 | |
| US7812007 | Aventis Pharma SA |
01-04-2005 (21-07-200 FR) |
“Method/Method of treating the proliferation of smooth muscle cells in a patient” | 23-07-2021 | |
| US7687274 | Aventis Pharma SA |
14-01-2008 (22-02-2004 FR) |
“Method/Method of assaying a sample chosen from heparin, low-molecular-weight heparin, ultra low molecular weight heparin, and oligosaccharides” | 25-03-2024 | |
| US8492352 | Sanofi-Aventis |
24-08-2009 (26-08-2008) |
“Product/ Synthetic polysaccharide of formula: Methyl (2-[N-(6-aminohexanoyl)]-2-deoxy-3,4-di-O-methyl-6-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulfonato-α-D-glucopyranoside sodium salt” | 01-09-2029 | |
| US8071570 | Aventis Pharma SA |
09-05-2011 (10-10-2002 FR) |
“Product/ A mixture of sulfated oligosaccharides” | 08-10-2023 | |
|
Tinzaparin B-eliminative cleavage by heparinase/enzymatic depolymerization |
EP0244235 | Novo Nordisk AS |
29-04-1987 (30-04-1986 DK) |
“Process/ process for the production of low molecular weight heparin (LMW-heparin) by enzymatic depolymerization of heparin” | 29-04-2007 |
| US5106734 | LEO/ Pharmion/Novo Nordisk AS |
29-04-1987 (30-04-1986 DK) |
“Process/ A continuous process for the production of a low molecular weight heparin product of a predetermined molecular weight by enzymatic depolymerization of heparin” | 21-04-2009 | |
|
Nadroparin Fraxiparin Nitrous acid depolymerization |
DE2944792 | Choay SA/ GlaxoSmithkline/Aspen |
11-06-1979 (11-06-1978 FR) |
“Compound/Mucopolysaccharide fraction obtainable from a material based on heparin” | 11-07-1999 |
| US4401662 | Choay SA |
06-10-1980 (05-10-1979 GB) |
“Compound/Oligosaccharide fraction (1) comprises not more than 8 saccharide units, (2) of which one is an N-sulfate-3-O-sulfate-D-glucosamine unit ….” | 30-08-2000 | |
| US4486420 | Choay SA |
14-09-1981 (06-11-1978 FR) |
“Compound/Heparinic mucopolysaccharide fractions” | 04-12-2001 | |
| EP0037319 | DROPIC/Choay |
20-03-1981 (20-03-1981 FR) |
“Process/ A process for the preparation of mucopolysaccharides having higher antithrombic activity and a lower ratio of YW/USP” | 20-03-2001 | |
| US4500519 | Choay SA |
20-11-1981 (06-11-1978 FR) |
“Process/ A process for making mucopolysaccharide heparinic fractions which have the L-iduronosyl-2-O-sulfate-(1-alpha-4)-N-sulfo-D-glucosamine-6-O-sulfate disaccharide structural units of heparin with the O-sulfated iduronic component of heparin” | 19-02-2002 | |
| US4607025 | Choay SA |
20-12-1982 (28-04-1981 FR) |
167894016700500“Compound/A disaccharide of the formula wherein M is hydrogen, --SO3 Na or acetyl; Z is --SO3 Na or acetyl and R1 is hydrogen, methyl or sodium.” | 19-08-2003 | |
| US4474770 | Choay SA |
22-08-1983 (05-10-1979 GB) |
“Compound/Oligosaccharide fraction (1) comprises not more than 8 saccharide units, (2) of which one is an N-sulfate-D-glucosamine unit” | 02-10-2001 | |
| US4686288 | DROPIC/Choay |
13-12-1984 (20-03-1980 FR) |
“Process/ A process for the preparation of mucopolysaccharides having higher antithrombic activity and a lower ratio of YW/USP and lower YW titer than the starting mucopolysaccharides” | 11-08-2004 | |
| US4692435A | Sanofi-Aventis/ Choay SA |
24-03-1985 (06-11-1978 FR) |
“Process/ process for obtaining heparinic mucopolysaccharides” | 24-12-2004 | |
| US4801583 | Choay SA |
15-05-1985 (15-01-1982 FR) |
10293351016000“A pure, synthetic tetrasaccharide having the formula:” | 31-01-2006 | |
| US4804652 | Choay SA |
19-02-1985 (06-11-1978 FR) |
“Process/A process for making mucopolysacharide heparinic fractions” | 14-02-2006 | |
| US4788307 | Choay SA and Sanofi-Aventis |
29-01-1987 (30-04-1986 FR) |
“Compound/An oligosaccharide fraction of the heparin chain which has antithrombotic activity in vivo (as measured by the (Yin-Wessler test) lower than that of heparin” | 29-11-2005 | |
| US5599801 | Choay SA and Sanofi-Aventis |
06-05-1994 (07-05-1993 FR) |
“Compound/ heparin fraction resulting from nitrous depolymerization of heparin of natural origin having a content of total N-nitroso compounds not exceeding 500 ppb” | 06-05-2014 | |
| EP2314632 | Aventis Pharma SA |
22-03-2005 (24-03-2004EP) |
14136392148100“Compound/Substantially pure compound having the formula:” | 22-03-2025 | |
| Ardeparin | US4281108 | Hepar Industries |
02-06-1980 (28-01-1980 US) |
“Process/ Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties” | 28-01-2000 |
| US4757057 | Pfizer Health AB |
07-01-1986 (09-08-1977 IT) |
“Process/Method of increasing the antithrombotic activity of mammalian blood relative to the anticoagulant activity” | 12-07-2010 | |
| US9068957 | Momenta Pharmaceuticals |
21-02-2012 (21-02-2011 US) |
“Method/Method of evaluating heparin preparations….” | 15-08-2032 | |
| Sevuparin | WO2009007224A1 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A |
10-07-2007 (10-07-2007 EP) |
11690355270500“Compound/ A heparin derivative having the formula”: | N/A |
| US9475888 | Dilafor AB |
19-12-2012 (19-12-2011 SE) |
“Compound/ chemically modified glycosaminoglycan, which glycosaminoglycan is selected from the group consisting of heparin and heparan sulfate” | 19-12-2032 | |
| US9480701 |
Modus Therapeutics AB/ Dilaforette AB |
19-12-2012 (19-12-2011 SE) |
“Compound/ Chemically modified heparin having an antifactor IIa activity and an antifactor Xa activity” | 19-12-2032 | |
| US9480702 |
Modus Therapeutics AB/ Dilaforette AB |
19-12-2012 (19-12-2011 SE) |
“Method/A method of treating sickle cell disease” | 19-12-2032 | |
| US10023659 | Dilafor AB |
19-06-2014 (19-06-2013 GB) |
“Process/Process for the preparation of a heparin derivative, the process comprising the consecutive steps of: (i) oxidising an acidic aqueous solution of unfractionated heparin by addition of an oxidising agent” |
10-09-2034 | |
| Parnaparin | US4791195 | Opocrin SpA |
21-10-1986 (08-03-1983 IT) |
“Compound/ heparin fraction which is a mixture of oligosaccharides containing an average of 13-17 monosaccharides” | 13-12-2005 |
| US4973580 | Opocrin SpA |
10-05-1989 (17-05-1985 IT) |
“Compound/ The oligosaccharide fraction from dermatan sulfate which has molecular weight 4800 daltons” | 27-11-2007 | |
| US5010063 | Alfa Wassermann SpA |
26-05-1989 (10-06-1988 IT) |
“Compound/ Heparin derivative which exhibits signals in the 13C-NMR spectrum at about 53 and about 54 ppm” | 26-05-2009 | |
| EP0347588 | Alfa Wassermann SpA |
19-05-1989 (10-06-1988 IT) |
“Compound/Heparin derivative characterized by signals in the 13C-NMR spectrum at 53 and 54 ppm” | 19-05-2009 | |
| US5104860 | Alfa Wassermann SpA |
09-01-1990 (30-01-1989 IT) |
“Compound/Heparin derivative having a 13 C-NMR spectrum in the zone between 102 and 92 p.p.m. with the presence of a characteristic signal at about 101.3 p.p.m.” | 09-01-2010 | |
| EP0380943 | Alfa Wassermann SpA |
12-01-1990 (30-01-1989 IT) |
“Process/ process for the preparation of new heparinic derivatives” | 12-01-2010 | |
| EP0497162 | Alfa Wassermann SpA |
17-01-1992 (30-01-1991 IT) |
“Process/ Process for preparing Pharmaceutical compositions containing orally absorbable glycosaminoglycans” | 17-01-2012 | |
| US5430132 | Alfa Wassermann SpA |
13-04-1993 (17-04-1992 IT) |
“Compound/Glycosaminoglycan of molecular weight 3,000-50,000 Daltons” | 13-04-2013 | |
| US5430133 | Alfa Wassermann SpA |
13-04-1993 (17-04-1992 IT) |
“Compound/Glycosaminoglycan of molecular weight 3,000-50,000” | 13-04-2013 | |
| US5410039 | Alfa Wassermann SpA |
07-03-1994 (29-03-1993 IT) |
“Process/Process for the synthesis of a product glycosaminoglycan” | 07-03-2014 | |
| Reviparin | EP1284717 | Abbott GmbH |
29-05-2001 (30-05-2000 DE) |
“Product/Formulation based on at least one heparin, glycosaminoglycan or heparinoids” | 27-12-2006 |
| Bemiparin | EP0293539 | Laboratorios Farmaceuticos Rovi S.A. |
22-07-1987 (05-01-1987 ES) |
“Process/Process of depolymerising heparine having an average molecular weight between 10.000 and 20.000 dalton to produce a depolymerized product” | 22-07-2007 |
| US981955 | Lopez Lorenzo L |
26-02-1990 (28-06-1988 US) |
“Process/Method of depolymerizing heparin comprising contacting a fully salified quaternary ammonium salt of heparin with a quaternary ammonium hydroxide in a non-aqueous polar solvent” | 26-02-2010 | |
| EP2308497 | Laboratorios Farmaceuticos Rovi S.A. |
30-06-2009 (07-01-2008 ES) |
“Product/Pharmaceutical composition comprising low or very low molecular weight heparins for use in the treatment of chronic ulcers, characterized in that the plasma half-life of the heparin is between 2.3 and 6.9 hours and the average daily dose of the heparin is between 5,400 and 10,000 IU/day” | 30-06-2029 | |
| EP2391352 | Laboratorios Farmaceuticos Rovi S.A. |
29-01-2010 (30-01-2009 EP) |
“A pharmaceutical form comprising a glycosaminoglycan selected from the group consisting of: bemiparin, fondaparinux and enoxaparin and its pharmaceutically acceptable salts” | 29-01-2030 | |
| US8802156 | Laboratorios Farmaceuticos Rovi S.A. |
29-07-2011 (14-11-2007 EP) |
“Product/Pharmaceutical form comprising a glycosaminoglycan with anions and a compound presenting cations of pH independent quaternary ammonium groups” | 02-04-2029 | |
| Certoparin | US4351938 | Riker Laboratories |
19-05-1980 (19-05-1980 US) |
“Process/Process which comprises reacting a heparin salt with from about 5 to 100 milliliters of an aqueous nitrous acid solution per gram of the heparin salt” | 19-05-2000 |
| Fondaparinux | US7468358 | ParinGenix/Cantex |
27-10-2004 (16-06-2004 US) |
“Method/Method for treating heparin-induced thrombocytopenia syndrome in a patient comprising administering sulfated polysaccharide comprises 2-O desulfated heparin or 2-O, 3-O desulfated heparin” | 07-09-2025 |
| US8288515 | Reliable Biopharmaceutical LLC. |
30-07-2010 (31-07-2009 US) |
“Compound/A compound of Formula I:” | 11-02-2031 | |
| US8420790 | Reliable Biopharmaceutical LLC. |
29-10-2010 (30-10-2009 US) |
“Process/Process for the preparation of a protected heparinic pentasaccharide precursor to Fondaparinux sodium having the structure” | 18-04-2031 | |
| US9089484 | Novo Nordisk AS |
28-03-2011 (26-03-2010US) |
“Method/A method for obtaining a reproducible bioavailability of fondaparinux” | 13-07-2032 | |
| EP2809678 | Reliable Biopharmaceutical LLC |
02-02-2012 (02-02-2011 PCT) |
“Process/Process for the preparation of a protected heparinic pentasaccharide precursor to Fondaparinux sodium” | 02-02-2032 | |
| US9255119 | Reliable Biopharmaceutical LLC |
18-04-2014 (31-07-2009 US) |
“Process/A process for making a compound of Formula I:” | 30-07-2030 | |
| CN109734757 | Huaibei Normal University |
11-03-2019 (11-03-2018 CN) |
“Process/Preparation method of a related substance B of fondaparinux sodium injection” | 11-03-2039 | |
| CN105175460 | Chongging University |
08-09-2015 (08-09-2014 CN) |
“Preparation method for monosaccharide fragment intermediate of fondaparinux sodium as anticoagulant drug” | 08-09-2035 | |
| Semuloparin AVE5026 |
EP1307491 (~WO 02008295) |
Aventis Pharma SA |
18-07-2001 (21-07-2000 FR) |
“Product/Mixtures of sulphated polysaccharides possessing the general structure of the constituent polysaccharides of heparin” | 18-07-2021 |
|
EP1556414 (~WO2004033503) |
Aventis Pharma SA |
08-10-2003 (10-10-2002 FR) |
“Product/Sulfated oligosaccharides having the general structure of the constituent polysaccharides of heparin” | 08-10-2023 | |
| EP1651677 | Aventis Pharma SA |
22-07-2004 (24-07-2003 EP) |
“Product/Oligosaccharide mixtures having the general structure of the constituent polysaccharides of heparin” | 22-07-2024 | |
| US8003623 | Aventis Pharma SA |
02-08-2007 (10-10-2002 FR) |
“Product/Mixture of sulfated oligosaccharides” | 19-08-2024 | |
| TW201038279 (~WO2010106519) | Sanofi-Aventis |
18-03-2010 (19-03-2009 EP) |
“Selection/A dose of 10 mg of AVE5026 for use in therapy in patients with severe renal impairment” | 18-03-2030 (If granted) | |
| WO2012072799A1 | Aventis Pharma SA |
02-12-2011 (02-12-2010 EP) |
“Assay/A method for the in vitro measurement of the biological activity of an Ultra Low Molecular Weight Heparin (ULMWH) sample, wherein said method is carried out relative to a standard comprising an ULMWH (semuloparin).” | N/A | |
| US9346894 | Sanofi-Aventis |
11-04-2012 (11-04-2011(FR) |
“A sulfonated polysaccharide having a polysaccharide of heparin which has a molecular weight of less than 8000 Daltons” | 23-09-2032 | |
|
RO-14 (a derivative of Bemiparin) |
EP1070503 | Laboratorios Farmaceuticos Rovi S.A. |
13-10-1999 (23-07-1999 ES) |
“Product/Composition of heparin of very low molecular weight, with the general formula:” | 13-10-2019 |
| US6384021 | Laboratorios Farmaceuticos Rovi S.A. |
03-11-1999 (23-07-1999 ES) |
“Product/Composition of heparin of very low molecular weight, with the general formula:” | 03-11-2019 | |
| EP2881404 | Laboratorios Farmaceuticos Rovi S.A. |
02-08-2013 (02-08-2012 ES) |
“Process/ Process for obtaining very low molecular weight heparin (VLMWH)” | 02-08-2033 |